AC Immune backs alpha-synuclein despite recent setbacks
The group’s purchase of Affiris’s Parkinson’s portfolio comes after stumbles from Roche/Prothena and Biogen.
Biopharma’s ballooning licensing deal bill
Up-front costs are higher than ever, with preclinical and phase 2 assets showing the most price inflation, according to a new analysis of licensing deal trends.
MPS 2021 – Denali disappoints in Hunter syndrome
The group will need longer-term data to justify its huge valuation.
Biopharma throws grease on the deal wheels
Company takeovers with promises of more cash down the road ticked up this year, a new Evaluate Vantage analysis finds.
